|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING |
|
|
|
| 68Ga-PSMA PET/CT Response and Clinical Outcomes in Patients Treated with Enzalutamide as First-Line Therapy for mCRPC: Results of a Prospective Study
|
| Emilio Francesco Giunta, MD
|
| Emilio Giunta presented a prospective study on 68Ga-PSMA PET/CT's effectiveness in assessing response and predicting clinical outcomes in mCRPC patients treated with first-line enzalutamide. The study found that 68Ga-PSMA PET/CT response is more informative than PSA monitoring for predicting progression-free survival.
|
|
|
|
|
|
| Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide vs Placebo + Enzalutamide as First-Line Treatment in Patients with mCRPC
|
| Arun Azad, PhD, MBBS, FRACP
|
| Arun Azad presented an analysis from the TALAPRO-2 study on using ctDNA burden as a prognostic biomarker for efficacy in mCRPC patients treated with talazoparib plus enzalutamide versus placebo plus enzalutamide. The study found that a high baseline ctDNA burden was associated with poorer radiographic rPFS in both treatment arms.
|
|
|
|
|
|
| Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2
|
| Karim Fizazi, MD, PhD
|
| Karim Fizazi presented a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency score developed for TALAPRO-2, a phase III study evaluating talazoparib plus enzalutamide vss placebo plus enzalutamide in mCRPC patients. The study found that the new HRD score, which incorporates gene expression and HRR12 genomic attributes, was associated with ctDNA HRR12m status and that patients with high HRD scores had numerically shorter, but not statistically significant, rPFS within each treatment arm.
|
|
|
|
|
|
|
|
|
|
|
| Exploration of Circulating Tumor Cell Conversion and CTC0 as Prognostic Biomarkers for Efficacy in TALAPRO-2
|
| Steven Yip, MD, MSc
|
| Steven Yip presented findings from TALAPRO-2 showing that CTC conversion and CTC0 are effective prognostic biomarkers for radiographic progression-free survival in mCRPC patients treated with talazoparib plus enzalutamide versus placebo plus enzalutamide. These biomarkers demonstrated significant prognostic value for rPFS at Weeks 9 and 17, supporting their utility in assessing treatment efficacy in this patient population.
|
|
|
|
|
|
| Biomarkers Associated with Outcomes from KEYLYNK-010: Pembrolizumab plus Olaparib vs Next-Generation Hormonal Agent in Previously Treated mCRPC
|
| Evan Y. Yu, MD
|
| Evan Yu presented findings from the KEYLYNK-010 study, which evaluated pembrolizumab plus olaparib versus next-generation hormonal agents in previously treated mCRPC. This study aimed to identify biomarkers associated with treatment outcomes.
|
|
|
|
|
|
| Rapid and Deep Prostate-Specific Antigen Response to Apalutamide plus ADT and Survival in mCSPC in Real World Practice in the US (OASIS Project)
|
| Benjamin L. Maughan, MD, PharmD
|
| Benjamin Maughan presented findings from the OASIS Project, a real-world study assessing the impact of rapid and deep PSA response to apalutamide plus androgen deprivation therapy on survival in mCSPC. Utilizing data from ConcertAI, they analyzed 183 patients treated with apalutamide+ADT and found that rapid and profound PSA reductions were associated with significantly improved overall survival, confirming previous findings from prospective studies.
|
|
|
|
|
|
| Association Between PSA Level 0.2 ng/mL and Risk of Radiological Progression in Patients with nmCRPC: Follow-up Analysis of ARAMIS
|
| Alicia Morgans, MD, MPH
|
| Alicia Morgans presented a follow-up analysis from the ARAMIS trial, examining the link between PSA levels <0.2 ng/mL and radiological progression risk in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The study found that patients treated with darolutamide plus ADT had significantly lower PSA progression and radiological progression compared to those receiving placebo plus ADT.
|
|
|
|
|
|
|
|
|
|
|
| Prognostic Implications of PSA Levels at 7 Months in mHSPC Treated with Enzalutamide: Landmark Analysis of ENZAMET (ANZUP 1304)
|
| Ronan Andrew McLaughlin, MD, MRCPATH, MBBCh
|
| Ronan McLaughlin presented a landmark analysis of the ENZAMET trial, focusing on the prognostic implications of PSA levels at 7 months in mHSPC treated with enzalutamide. The analysis revealed that achieving a PSA nadir of ≤0.2 ng/mL at 7 months was associated with significantly longer 5-year overall survival, irrespective of treatment arm and metastatic burden.
|
|
|
|
|
|
| Post-Progression Survival of Patients with mHSPC Who Received Darolutamide or Placebo: Post Hoc Analysis of ARASENS
|
| Marc-Oliver Grimm, MD
|
| Marc-Oliver Grimm presented a post hoc analysis of ARASENS focusing on post-progression survival in mHSPC patients treated with darolutamide or placebo. The analysis revealed that darolutamide, when added to ADT and docetaxel, increased overall survival and delayed progression to mCRPC.
|
|
|
|
|
|
| IMPLEMENT: Physicians' Use of First-Line Treatment Intensification in mCSPC: A Discrete Choice Experiment
|
| Stacy Loeb, MD
|
| Stacy Loeb presented findings from the IMPLEMENT study, focusing on physicians' use of first-line treatment intensification in mCSPC. The study identified key differences between oncologists and urologists in the helpfulness of resources for decision-making, highlighting variability in clinical practice needs. These findings offer insights for developing specialty-tailored tools to enhance guideline-concordant treatment intensification for mCSPC.
|
|
|
|
|
|
| Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL)
|
| Edwin Posadas, MD, FACP
|
| Edwin Posadas presented the initial results of STEEL, a study on intensification of androgen deprivation therapy with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation. While there was a trend towards improved progression-free survival with enzalutamide, it did not reach statistical significance at the time of analysis.
|
|
|
|
|
|
|
|
|
|
|
| ctDNA Fraction as a Predictor of Treatment Efficacy in a Randomized Phase 2 Trial of [177Lu] Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing After Docetaxel |
| Edmond Michael Kwan, PhD, MBBS, FRACP |
| Edmond Kwan presented an exploratory analysis from the TheraP ANZUP 1603 trial, investigating circulating tumor DNA fraction as a predictor of treatment efficacy in mCRPC patients treated with [177Lu] Lu-PSMA-617 versus cabazitaxel. The analysis found that lower ctDNA% (<2%) was associated with significantly better PSA responses and longer progression-free survival with LuPSMA compared to cabazitaxel. |
|
|
|
|
|
| PLATIPARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients with mCRPC with Homologous Recombination DNA Repair Deficiency |
| Ruben Raychaudhuri, MD |
| Ruben Raychaudhuri presented results from the PLATIPARP phase II trial, which evaluated induction chemotherapy with docetaxel plus carboplatin followed by maintenance rucaparib in mCRPC patients with HRR gene alterations. The study highlighted the potential benefit of this treatment sequence in BRCA-mutated patients and the need for further research on optimal sequencing of platinum and PARP inhibitors. |
|
|
|
|
|
| ODM-209, a CYP11A1 Inhibitor in Patients with mCRPC: Results from the STESIDES Phase 1 Study |
| Karim Fizazi, MD, PhD |
| Karim Fizazi presented the phase I STESIDES study results on ODM-209, a CYP11A1 inhibitor, in mCRPC patients. The study showed that ODM-209 effectively suppressed steroid hormone production and achieved notable PSA responses, particularly in patients with AR-LBD mutations. However, the treatment was associated with manageable adverse events, including fatigue and peripheral edema, and adrenal insufficiency in 5% of patients. |
|
|
|
|
|
